[Chemotherapy of advanced breast cancer--actual results ].
The preliminary results of a prospective controlled study for a first-line-therapy in women with hormone-resistant advanced breast cancer are reported. Two therapy-regimens were compared: 1) cyclophosphamide, methotrexate and ftorafur (CMFt) and 2) cyclophosphamide and ftorafur (CFt). The overall objective response rate for both treatment groups was 30%, the duration of remission was 10 months in the CMFt-regimen and 5 months in the CFt-regimen. 21 patients were subsequently treated with the non-cross-resistant combination adriamycin and vincristine (AV) after either relapse or failure of the firstline modalities. 33% of the AV-group obtained further palliation with a median duration of 7 months, objective response was not seen.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000556:secondary; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives*; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D011379:Prognosis; D005641:Tegafur / Q000008:administration & dosage*; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D005641:Tegafur; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
Neue Ergebnisse bei der Chemotherapie des fortgeschrittenen Mammakarzinoms.